Amylin’s Symlin Diabetes Therapy Gets FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
The approval follows the company’s submission of a re-analysis of hypoglycemia data in response to an FDA “approvable” letter. The product is approved as an adjunct treatment for Type 1 and 2 diabetes.
You may also be interested in...
Amylin Halts Development Of Symlin With Approved Appetite Suppressants
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.
Amylin Halts Development Of Symlin With Approved Appetite Suppressants
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.
Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: